The FLOW-AF multicenter, randomized controlled trial shows Ablacon's Electrographic Flow® (EGF®) Mapping software (Ablamap®) results in improved ablation outcomes in persistent atrial fibrillation

/PRNewswire/ -- Ablacon, Inc., an Ajax Health and Zeus Health-backed developer of an innovative mapping system to guide the treatment of atrial fibrillation...

Related Keywords

Boston ,Massachusetts ,United States ,Duke Rohlen ,David Haines ,Ablacon Ablamap ,Vivek Reddy ,Ablacon Inc ,Prnewswire Ablacon Inc ,Ajax Health ,Zeus Health Backed ,Late Breaking Clinical Trials ,Scientific Advisory Board ,Menlo Park ,Healthquest Capital ,Polaris Partners ,Ablacon ,Nc ,